Cytovance Capabilities Update October 2026: Large Molecule

Biologics programs can become more complex as they move from early development toward GMP manufacturing and commercialization. Cytovance Biologics offers integrated mammalian and microbial capabilities designed to support that progression from cell line or strain development through process development, analytical services, GMP manufacturing, and commercial supply.

Its Oklahoma City facilities provide mammalian capacity up to 2,000 L and microbial fermentation up to 1,000 L, alongside perfusion capabilities, formulation development, stability studies, and early-phase fill-finish. A predominantly U.S.-based supply chain also provides an option for companies looking to simplify logistics and reduce dependence on overseas manufacturing. With experience spanning antibodies, fusion proteins, bispecifics, cytokines, and other biologics, the organization supports a broad range of development needs.

Watch the webinar for a closer look at the capabilities available across the development lifecycle.